Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07123779
PHASE1/PHASE2
HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)
Sponsor: 35Pharma Inc
View on ClinicalTrials.gov
Summary
Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
Official title: Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Participants With Pulmonary Hypertension and HFpEF
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2026-08
Completion Date
2030-01
Last Updated
2026-08-17
Healthy Volunteers
No
Interventions
BIOLOGICAL
HS235
Subcutaneous Injection
OTHER
Placebo
Subcutaneous Injection
Locations (1)
Investigational Site-101
Greenville, South Carolina, United States